Use of megestrol acetate in advanced breast cancer on a single-daily-dose schedule.
Twenty patients with metastatic breast carcinoma received megestrol acetate following additive or ablative therapy. The drug was given in a single oral dose of 160 mg daily to all patients. Side effects and response to therapy appeared comparable to those obtained when the drug is given on a multiple-daily-dose schedule. This small series suggests that megestrol acetate can be used as a single daily dose with comparable therapeutic efficacy and no change in the expected side effects.
D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000188:drug therapy*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008535:Megestrol / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D019290:Megestrol Acetate; D008875:Middle Aged; D010349:Patient Compliance; D011960:Receptors, Estrogen / Q000032:analysis
D011960:Receptors, Estrogen; D008535:Megestrol; D019290:Megestrol Acetate